The causes of male infertility have been well delineated in numerous textbooks and articles. These are divided into six major categories such as failure of spermatogenesis, failure of sperm maturation, failure of sperm transportation, failure of semen composition, failure of hormonal system and failure of ejaculation. Besides these, the motile activity of sperm has been regarded as an important factor for the impregnation This clinical study has been undertaken to examine the effects of hemologous human semen mixtures upon the motile time of the spermatozoa, and the result are presented as follows; Group 1, Mixture of Normospermia and Normospermia: 10 mixtures Normospermia-A: 471. 9 minutes of aver age sperm motile time Normospermia-B: 369. 4 minutes of average sperm motile time Normo-A+Normo-B mixture: 452. 5 minutes of average sperm motile time Group 2, Mixture of Normospermia and Oligospermia: 10 mixtures Normospermia: 445.3 minutes of average sperm motile time Oligospermia: 376.2 minutes of average sperm motile time Normo+Oligo mixture: 456. 1 minutes of average sperm motile time Group 3, Mixture of Normospermia and Azoospermia; 8 mixtures Normospermia: 433. 3 minutes of average sperm motile time Azoospermia: Normo.+Azoo. mixture: 455. 1 minutes of average sperm motile time Group 4, Mixture of Oligospermia and Azoospermia; 6 mixtures Oligospermia: 343. 6 minutes of average sperm motile time Azoospermia: Oligo.+Azoo. mixture: 348. 1 minutes of average serum motile time In In conclusion, 1. no mutual spermicidal effect but tendency toward enhancement of sperm motile time 2. no sperm agglutinating phenomenon nor sperm immobilizing effect were noted in various semen mixtures 3. posibilities of clinical application such as AID arc considerable and 4. further studies are needed in conjunction with the serum autoimmune mechanism.
Azoospermia ; Ejaculation ; Humans* ; Infertility, Male ; Male ; Oligospermia ; Semen* ; Sperm Immobilizing Agents ; Sperm Maturation ; Sperm Transport ; Spermatogenesis ; Spermatozoa*

PURPOSE: Neutropenia is common in patients receiving myelotoxic chemotherapy. The aim of this study is to compare the efficacy, safety and adverse events between prophylactically administered Leukokine and Grasin. METHODS: An open-label, randomized, phase III study was designed to compare the effects of a subcutaneous injection of Leukokine (CJ Corp.) 100mug/m2 with Grasin (Jeil Pharm. Inc.) in patients receiving induction chemotherapy for acute leukemia. All patients received one dose of G-CSF every day during the study period. Total period of G-CSF injection was not over 14 days. The administration of G-CSF began on day 14 after beginning of chemotherapy under CCG strategy. In other chemotherapies, the injection of G-CSF started on day 1 from end of chemotherapy. Injection of G-CSF stopped after absolute neutrophil count recovery was achieved. RESULTS: The median numbers of times of administration were 9.6 (2~14) /cycle for Leukokine and 8.8 (2~14) /cycle for Grasin. The time to needed for neutrophil recovery more than 1, 000/mm3 was 6.6 4.9 day and 4.7 4.8 day of the Leukokine and Grasin, respectively (P=0.14). The mean duration of neutropenia less than 500/mm3 was 7.6 5.6 days for Leukokine and 6.1 6.0 days for Grasin (P=0.28). The results for the two groups were also not significantly different in adverse events, physical examination and laboratory findings. CONCLUSION: Leukokine was safe and well tolerated in these patients population. Injection of Leukokine provided neutrophil recovery with safety and efficacy similar to that provided by Grasin.
Drug Therapy ; Granulocyte Colony-Stimulating Factor ; Humans ; Induction Chemotherapy* ; Injections, Subcutaneous ; Leukemia* ; Neutropenia ; Neutrophils ; Physical Examination